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OBJECTIVE: Cigarette smoking is the main risk factor for bladder cancer development. Among the mediators of this
effect of smoking is nuclear factor-kappa B. Curcumin suppresses cellular transformation by downregulating the activity
of nuclear factor-kappa B. Prima-1 is a compound that induces apoptosis in human tumor cells, restoring the function of
mutant p53. Our study aimed to evaluate the effects of curcumin and prima-1 in an animal model of bladder cancer.
METHODS: Tumor implantation was achieved in six- to eight-week-old female C57BL/6 mice by introducing MB49
bladder cancer cells into the bladder. Intravesical treatment with curcumin and Prima-1 was performed on days 2, 6,
10, and 14. On day 15, the animals were sacrificed. Immunohistochemistry was used to determine the expression of
cyclin D1, Cox-2, and p21. Cell proliferation was examined using PCNA.
RESULTS: Animals treated with curcumin exhibited a higher degree of necrosis than animals in other groups.
Immunohistochemistry showed reduced expression of cyclin D1 in the curcumin-treated group. All of the cells in
mice treated with curcumin were p21 positive, suggesting that the p53 pathway is induced by this compound.
Prima-1 did not induce any change in tumor size, necrosis, cell proliferation, or the expression of proteins related to
the p53 pathway in this animal model.
CONCLUSION: Curcumin showed activity in this animal bladder cancer model and probably acted via the regulation
of nuclear factor-kappa B and p53. Therefore, curcumin is a good choice for the use in clinical trials to treat
superficial bladder cancer as an alternative to bacillus Calmette-Guerin. In contrast, Prima-1 does not seem to have
an effect on bladder cancer.
KEYWORDS: Bladder cancer; Treatment; Curcumin, Prima-1; Apoptosis.
Watanabe FT, Chade DC, Reis ST, Piantino C, Dall’ Oglio MF, Srougi M, et al. Curcumin, but not Prima-1, decreased tumor cell proliferation in the
syngeneic murine orthotopic bladder tumor model. Clinics. 2011;66(12):2121-2124.
Received for publication on July 7, 2011; First review completed on August 8, 2011; Accepted for publication on August 10, 2011
E-mail: katiaramos@uol.com.br
Tel.: 55 11 30617183
INTRODUCTION
Cancer of the urinary bladder is diagnosed in approxi-
mately 71,500 people in the United States, and approximately
14,500 individuals die of the disease each year.1 The condition
affects individuals 60 to 70 years of age, and racial and ethnic
variations in its incidence have been observed.2-4 Current
treatment for superficial urothelial carcinoma includes endo-
scopic tumor resection, followed by intravesicular adminis-
tration of bacillus Calmette-Guerin (BCG), a treatment that
has well-known side effects.5 Topical chemotherapy with
mitomycin, thiotepa, and epirubicin has been used as an
alternative, but this treatment has no impact on long-term
survival or disease progression. The toxicity and inefficacy of
these intravesicular agents prompted us to explore new
treatments for superficial urothelial carcinoma of the bladder.
The use of tobacco is one of the main causes of bladder
cancer development, which is due to the presence of certain
compounds present in cigarette smoke (CS). Exposure to
some of these compounds is associated with the induction of
nuclear factor-kappa B (NF-kB). We previously studied the
effects of curcumin in an orthotopic murine bladder tumor
model, demonstrating that curcumin has an inhibitory effect
on bladder urothelial cancer, possibly by downregulating NF-
kB-related genes,6 Therefore, curcumin could be an option for
the treatment of urothelial neoplasms.7 The tumor suppressor
protein p53 inhibits tumor growth primarily through its
ability to induce apoptosis. Mutations in p53 occur in at least
50% of human tumors, and p53 is characteristically mutated
in high-grade, invasive urothelial carcinoma. Prima-1 is a low-
molecular-weight compound able to induce apoptosis in
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human tumor cells by restoring the transcriptional transacti-
vation function of mutant p53. In the presence of Prima-1,
mutant p53 proteins regain their sequence-specific DNA
binding ability and their active conformations in vitro and in
living cells. In vivo studies in mice revealed that Prima-1 has
an anti-tumor effect with no apparent toxicity.8
Now, using the same animal model,9 we assessed
whether curcumin function is enhanced by Prima-1 or if
there is a specific role of curcumin that could be used to
treat bladder cancer.
MATERIALS AND METHODS
Orthotopic Tumor Implantation
Six- to- eight-week-old female C57BL/6 mice were put
under general anesthesia with an intraperitoneal injection of
150 mL of a mixture of xylazine-ketamine-PBS (15158). Then,
a 24-gauge Teflon intravenous IV catheter was inserted
through the urethra into the bladder using xylocaine gel. To
prepare the bladder for tumor implantation, a chemical lesion
on the bladder wall was made by intravesicular administra-
tion of 0.15 M AgNO3 (10 mL). This promoted an adequate
and controlled diffuse cauterization of the bladder wall. After
10 seconds, the contents were washed out by transurethral
infusion of PBS. Then, a suspension of 56105 viable tumor
cells of the murine transitional cell carcinoma cell line MB49
(MB49) was introduced into the bladder. The day of the
administration of tumor cells was considered to be Day 1.
Treatment
Treatment was performed by administering the tested
drugs four times. Twenty-four hours following tumor cell
introduction (Day 2), therapy with 100 mL intravesicular
curcumin (100 mM - Sigma) or 100 mL Prima-1 (100 mM)
was initiated. The ‘‘curcumin+Prima-1’’ treatment group
received 100 mL of a 151 mixture of curcumin (200 mM) and
Prima-1 (200 mM). Mice were assigned to 1) the control
group, which received 100 mL saline (n = 10); 2) the ‘‘only
tumor’’ group (n = 10), which received tumor cells and were
not handled again until sacrifice; and 3) treatment groups
receiving curcumin (n = 10), Prima-1 (n = 10) or a mixture of
both (n = 10). The other three drug applications occurred on
days 6, 10, and 14.
Assessment of the tumors
The mice were evaluated on a daily basis for viability and
gross hematuria. At Day 15, they were sacrificed by CO2
inhalation. The bladder, lungs, kidneys, and liver were
resected for histological examination.
Histopathology analysis
The specimens were fixed in 10% buffered formalin and
sectioned for histological examination. For the bladder
slides, tumors were measured, and the degree of necrosis
was recorded. Sections of the lungs, kidney, and liver were
also analyzed to identify the presence of metastases.
Immunohistochemistry
Three-micrometer sections from the paraffin block were
placed on adhesive-coated slides. For antigen retrieval, the
slides were placed in citrate buffer (1 mM, pH 6.0) and
heated for 30 min in the steamer. The slides were then
incubated overnight at 4 C˚ with monoclonal antibodies
targeting cyclin D1 (Spring, 15100 dilution), Cox-2 (Spring,
15100), p21 (Millipore, 1550), and PCNA (Dako, 15200). The
LSAB system was used for immunostaining. The color was
developed using a 3,39-diaminobenzidine substrate-chromo-
gen solution, followed by counterstaining with Harris
hematoxylin. Samples were then dehydrated, preserved
with a cover slip and reviewed using light microscopy.
Statistical analysis
Statistical analyses were performed using ANOVA and
chi-squared tests for the evaluation of histological char-
acteristics and immunohistochemistry findings between
different groups of animals using the GraphPad Prism 5.0
software.
RESULTS
Initially, the study included 50 animals distributed among
the groups. Five animals in the control (saline) group were
excluded from the study due to a possible bladder infection
observed by microscopy. Two animals died prematurely,
probably as the result of the anesthesia. Five mice died later,
possibly due to the neoplasm. In four animals, the tumor
implantation was not successful. These animals were also
excluded from the study. After these exclusions, the study
included 34 mice.
The results are shown in Table 1. We found that animals
treated with curcumin showed a higher degree of necrosis
than the mice in all other groups. The mean percentage of
tumor necrosis in mice treated with curcumin was 67%,
whereas in the other groups, the mean was only 27%
(p,0.001).
The mean tumor sizes at the end of the study in the
untreated and saline-injected groups were 4.2 mm and
6.2 mm, respectively. Although these sizes seem much
larger than that in the curcumin-treated group (mean size
2.9 mm), there were no statistically significant differences.
We next compared the expression of genes regulated by NF-
kB. Cyclin D1 was expressed in fewer cells in the group treated
with curcumin, with a mean percentage of 23% compared with
34%, 53%, 50%, and 60% in the Prima-1, curcumin and Prima-
1, saline control, and untreated control groups, respectively
(p,0.001). There was no statistically significant difference in
Cox-2 expression between groups (p= 0.064).
We also analyzed the expression of p21, which is
regulated by p53, a frequently mutated gene in invasive
bladder cancer. Because Prima-1 restores the activity of the
mutated p53 protein, we expected to find some difference in
the expression of p21 among these groups of animals.
However, there were no differences in the expression of p21
between the different groups of mice (p= 0.55).
In addition, proliferative activity, as measured using
PCNA, was similar among the treatment groups.
DISCUSSION
Our results confirm our previous finding that intravesi-
cular injection of curcumin was able to promote bladder
tumor necrosis. Although there was no statistically sig-
nificant difference in tumor size between the different
groups, tumors treated with curcumin were smaller,
especially when compared with those exposed to saline
alone (mean 2.85 mm vs. 6.23 mm).
Recently, we showed that curcumin promotes apoptosis
in MB49 mouse bladder tumor cells in vitro and causes a
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decrease in tumor size in vivo in the syngeneic orthotopic
murine bladder cancer model.7,8 Garg and Aggarwal10
previously discovered that curcumin functions by modulat-
ing TNF-induced NF-kB activation. NF-kB activates the
transcription of genes related to cell proliferation, including
cyclin D1 and Cox-2. We confirmed that curcumin affects
NF-kB function in our animal model, reducing the expres-
sion of cyclin D1 in mice treated with this substance
compared to untreated animals, in agreement with our
previous results. The mean percentage of cyclin D1-positive
tumor cells was 23% in animals treated with curcumin and
49% in untreated mice (p,0.01). However, we did not find
differences in the regulation of other genes related to the
NF-kB pathway among the groups of animals. The Cox-2
expression profile varied widely in animals treated with
curcumin, Prima-1, or both. In addition, there was no
difference in terms of cell proliferation.
Chen et al.11 were able to show that BCG activates
multiple intracellular signaling pathways, including NF-kB,
in MB49 cultures. BCG is the standard of care for the
treatment of low-grade pTa and pT1 urothelial carcinomas
and reduces tumor recurrence without affecting specific
cancer survival rates. However, one-third of patients fail to
respond to BCG, and BCG can cause many side effects. In
this in vivo mouse model, we demonstrated that curcumin
affects tumor behavior in a manner similar to that of BCG
without side effects. Curcumin, a compound derived from
Curcuma longa Linn, is not easily absorbed, and the
possibility of using it as an intravesicular anti-cancer drug
is very attractive.
The rationale for testing Prima-1 in this animal model was
that Prima-1 can restore p53 transcriptional activity. We
expected to observe an effect of Prima-1 on tumor size,
apoptotic index or p21 protein expression either when
Prima-1 was used alone or when it was used together with
curcumin. The transcription of p21/WAF1 is controlled by
p53, and the loss of its expression has been related to poor
prognosis in bladder cancer.12 However, we saw no
differences in these studies between animals treated with
or without Prima-1. We can speculate that p53 plays no role
in this tumor model.
However, 100% of tumor cells in mice treated with
curcumin were p21 positive, suggesting that p53 can be
induced by this compound, as previously observed in in
vitro and in vivo models of bladder cancer13 and in other
tumors, such as neuroblastomas14 and adenocarcinomas of
the prostate15 and colon.16
We conclude that curcumin is a good choice for use in
clinical trials as an alternative to BCG to treat superficial
bladder cancer because curcumin controls the genetic
pathways important in the carcinogenesis of this neoplasia.
In contrast, Prima-1 does not seem to have an effect on this
tumor.
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